Demographic and anthropometrical analysis and genotype distribution of chronic hepatitis C patients treated in public and private reference centers in Brazil
AUTOR(ES)
Focaccia, R., Baraldo, D.C.M., Ferraz, M.L.G., Martinelli, A.L.C., Carrilho, F.J., Gonçales Jr., F.L., Pedroso, M.L.A., Coelho, H.S.M., Lacerda, M.A., Brandão, C.E., Mattos, A.A., Lira, L.G.C., Zamin Jr., I., Pinheiro, J.O.P., Tovo, C.V., Both, C.T., Soares, J.A.S., Dittrich, S.
FONTE
Brazilian Journal of Infectious Diseases
DATA DE PUBLICAÇÃO
2004-10
RESUMO
Hepatitis C virus (HCV) infection is a serious public health problem, since 80% to 85% of HCV carriers develop a persistent infection that can progress into liver cirrhosis and hepatocarcinoma. Considering that the response of hepatitis C patients to combination therapy with interferon and ribavirin depends on HCV characteristics as well as on host features, we made a retrospective analysis of demographic and anthropometrical data and HCV genotype distribution of chronic hepatitis C patients treated in public and private reference centers in Brazil. The medical records of 4,996 patients were reviewed, 81% from public and 19% from private institutions. Patients' median age was 46 years, and there was a higher prevalence of male (62%) and white patients (80%). The analysis of HCV-infecting strains showed a predominance of genotype 1 (64%) over genotypes 2 and 3. The patients' mean weight was 70.6 kg, and 65% of the patients weighed less than 77kg. Overweight and obesity were observed in 37.8% and 13.6% of the patients, respectively. Since a body weight of 75 kg or less has been considered an independent factor that significantly increases the odds of achieving a sustained virological response, the Brazilian population seems to have a more favorable body weight profile to achieve a sustained response than the American and European populations. The finding that 65% of chronic hepatitis C patients have a body weight of 77 kg or less may have a positive pharmacoeconomic impact on the treatment of genotype 1 HCV patients with weight-based doses of peginterferon.
Documentos Relacionados
- Phylogenetic analysis and genotype distribution of Hepatitis B Virus (HBV) in Roraima, Brazil
- High incidence of tuberculosis in patients treated for hepatitis C chronic infection
- Quality of life in Brazilian patients with treated or untreated chronic hepatitis C
- Hepatic histology of patients with HIV infection and chronic hepatitis C treated with interferon.
- Chronic Hepatitis C treatment for genotype 2 or 3 in Brazil: cost effectiveness analysis of peginterferon plus ribavirin as first choice treatment